| |
CVD HR (95%CI)
|
Hard CVD HR (95%CI)
|
|---|
|
E/N
|
Model 1
|
Model 2
|
E/N
|
Model 1
|
Model 2
|
|---|
|
FPG-WHO (mmol/L)
|
|
< 6.1
|
169/327
|
1.00
|
1.00
|
66/327
|
1.00
|
1.00
|
|
6.1–6.9
|
21/44
|
0.92 (0.58–1.45)
|
0.87 (0.55–1.39)
|
10/44
|
1.13 (0.58–2.21)
|
0.97 (0.49–1.93)
|
|
≥ 7
|
30/37
|
2.02 (1.36–3.00)
|
2.07 (1.39–3.12)
|
13/37
|
1.95 (1.07–3.53)
|
2.02 (1.07–3.80)
|
|
FPG-ADA (mmol/L)
|
|
< 5.6
|
129/253
|
1.00
|
1.00
|
45/253
|
1.00
|
1.00
|
|
5.6–6.9
|
61/118
|
1.07 (0.79–1.46)
|
1.05 (0.77–1.44)
|
31/118
|
1.62 (1.03–2.57)
|
1.52 (0.95–2.45)
|
|
≥ 7
|
30/37
|
2.09 (1.40–3.12)
|
2.15 (1.41–3.27)
|
13/37
|
2.28 (1.23–4.22)
|
2.41 (1.25–4.67)
|
|
2 h-PCPG (mmol/L)
|
|
< 7.8
|
123/240
|
1.00
|
1.00
|
50/240
|
1.00
|
1.00
|
|
7.8–11.0
|
54/105
|
1.01 (0.73–1.39)
|
0.97 (0.70–1.36)
|
20/105
|
0.93 (0.55–1.56)
|
0.90 (0.53–1.55)
|
|
≥ 11
|
43/63
|
1.48 (1.04–2.10)
|
1.46 (1.02–2.11)
|
19/63
|
1.59 (0.93–2.70)
|
1.54 (0.88–2.70)
|
- Model 1: age and sex
-
Model 2: model 1+ body mass index, current smoking, family history of premature CVD, hypertension, hypercholesterolemia, low HDL-C, heart rate, use of aspirin, use of beta blockers and low physical activity.
- E event in the target group, N total sample size in the target group, CVD cardiovascular disease, CHD coronary heart disease, HR hazard ratio, CI confidence interval, FPG fasting plasma glucose, 2h-PCPG 2h post challenge plasma glucose, WHO World Health Organization, ADA American Diabetes Association
